Literature DB >> 17095714

The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells.

Yasufumi Sato1, Hikaru Sonoda.   

Abstract

Biological phenomena are under the precise control by the genome. For the regulation of angiogenesis, proangiogenic genes such as VEGFs and angiopoietins are highly conserved, act specifically on endothelial cells, and play a fundamental role. In this sense, nature should prepare specific antiangiogenic genes as well. However, this counterpart of genomic regulation of angiogenesis remains to be established. We recently isolated a novel endothelium-derived angiogenesis inhibitor and named it vasohibin. Vasohibin is dominantly expressed in endothelial cells, induced by the stimulation with VEGF or FGF-2, and selectively affects on endothelial cells and inhibits angiogenesis. Although the mechanism of how vasohibin inhibits angiogenesis remains to be elucidated, our discovery of vasohibin as an endothelium-derived VEGF-inducible angiogenesis inhibitor should shed light on the genomic basis of the negative regulation of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095714     DOI: 10.1161/01.ATV.0000252062.48280.61

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

2.  Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study.

Authors:  R Jain; L Poisson; J Narang; L Scarpace; M L Rosenblum; S Rempel; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

3.  Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients.

Authors:  Shuji Mikami; Mototsugu Oya; Takeo Kosaka; Ryuichi Mizuno; Yasumasa Miyazaki; Yasufumi Sato; Yasunori Okada
Journal:  Lab Invest       Date:  2017-03-13       Impact factor: 5.662

4.  TJ0711, a novel vasodilatory β-blocker, protects SHR rats against hypertension induced renal injury.

Authors:  Juan Yang; Yong Ning; Jun Qiu; Jin-Seng He; Wei Li; Zu-Fu Ma; Ju-Fang Shao; Yue-Qiang Li; Rui Zeng; Meng Zhang; Jia Cheng; Su-Fang Chen; Gang Xu; Cong-Yi Wang; Ying Yao
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

5.  Canonical Wnt signaling in megakaryocytes regulates proplatelet formation.

Authors:  Iain C Macaulay; Jonathan N Thon; Marloes R Tijssen; Brian M Steele; Bryan T MacDonald; Gerardene Meade; Philippa Burns; Augusto Rendon; Vishal Salunkhe; Ronan P Murphy; Cavan Bennett; Nicholas A Watkins; Xi He; Desmond J Fitzgerald; Joseph E Italiano; Patricia B Maguire
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

6.  Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1.

Authors:  Shi-you Zhou; Zhao-lian Xie; Ou Xiao; Xiao-ru Yang; Boon Chin Heng; Yasufumi Sato
Journal:  Mol Vis       Date:  2010-07-26       Impact factor: 2.367

Review 7.  Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.

Authors:  Jian Chen; Yingfeng Lu; Yunliang Zheng
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

8.  A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1.

Authors:  Yichao Yan; Zhanlong Shen; Yingjiang Ye; Kewei Jiang; Hui Zhang; Chao Shen; Harri Mustonen; Pauli Puolakkainen; Shan Wang
Journal:  Med Oncol       Date:  2013-12-24       Impact factor: 3.064

9.  The prognostic significance of vasohibin-1 expression in patients with prostate cancer.

Authors:  T Kosaka; Y Miyazaki; A Miyajima; S Mikami; Y Hayashi; N Tanaka; H Nagata; E Kikuchi; K Nakagawa; Y Okada; Y Sato; M Oya
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

10.  Vasohibin 2 decreases the cisplatin sensitivity of hepatocarcinoma cell line by downregulating p53.

Authors:  Zhanjun Li; Min Tu; Bei Han; Yuqing Gu; Xiaofeng Xue; Jie Sun; Qianqian Ge; Yi Miao; Zhuyin Qian; Wentao Gao
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.